Latest Myeloproliferative disease Stories
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp.
- PharmaEssentia and AOP Orphan announce completion of recruitment of the pivotal European Phase III trial PROUD-PV (www.proud-pv.com) to support global marketing of P1101 (Ropeginterferon alfa-2b).
Trial Meets Primary Endpoint in Intent-to-Treat Population SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
MILWAUKEE, July 23, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin
Melbourne researchers have solved a puzzle as to how an essential blood-making hormone stimulates production of the blood clotting cells known as platelets.
ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug.